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Deﬁbrillation threshold (DFT) testing is usually recommended after device implantation to conﬁrm
appropriate implantable cardioverter deﬁbrillator (ICD)/cardiac resynchronization therapy deﬁbrillator
(CRT-D) function [1,2]. However, induction of ventricular ﬁbrillation may result in hemodynamic
compromise, and cardioversion itself may cause myocardial injury [3,4]. We report on a CRT-D patient
with acute myocardial infarction who died due to multiple organ failure 1 day after DFT testing. Our
case emphasizes the importance of deciding whether DFT testing should be performed for patients with
very severe heart failure in the acute stage of myocardial infarction.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Case report
A 59-year-old male was referred to our hospital in cardiogenic
shock. A 12-lead electrocardiogram showed abnormal Q-waves in
V1–V4 leads and complete atrioventricular block; the patient was
diagnosed with acute myocardial infarction (AMI) (Fig. 1). Upon
arrival, the patient was unconscious, and his blood pressure was
60 mmHg; therefore, endotracheal intubation and ventilation
were immediately performed. Emergency percutaneous coronary
intervention (PCI) was performed under temporary pacing for the
left main coronary trunk (75% stenosis-0%) and left anterior
descending artery (90% stenosis-0%). Left ventricular wall
motion showed severe hypokinesis at the anteroseptal region
with an ejection fraction of 33%. Sinus rhythm was restored after
PCI; however, atrioventricular block frequently occurred, and we
considered the patient’s condition an indication for permanent
pacemaker implantation. Echocardiography showed severely
impaired left ventricular wall motion with low EF of 33.6% and
cardiac dyssynchrony. The QRS duration was widened to 145 ms
and showed a right bundle branch block conﬁguration. The
patient was on b-blockade, ACE-inhibitor, and amiodarone. Mex-
iletine was also given intravenously for frequent ventricular
tachycardia (VT). Despite the use of these antiarrhythmic agents,
VT still occurred frequently and cardioversion was performed
several times. Cardiac resynchronization therapy deﬁbrillator
(CRT-D) therapy was selected for this patient and the devicert Rhythm Society. Published by E
akai).was implanted on June 3, 2008, 1 week after PCI. We performed
this implantation in the acute stage of MI because the patient had
an advanced AV block and needed pacing therapy. At ﬁrst, the
right ventricular (RV) lead was inserted into RV apex. However,
RV sensing was not satisfactory (o3.0 mV) and only the RV
septum area yielded a slightly better result. After insertion of
the RV lead, we performed coronary venography and selected a
preferred site for LV pacing in the posterior coronary vein.
Ultimately, the atrial pacing lead was located in the right atrial
(RA) appendage with sensing 4.1 mV, the RV pacing lead was
located in the ventricular septum area with sensing 4.3 mV, and
the LV pacing lead was located in the posterior coronary vein
(generator: Medtronic CONCERTO C154DWK; RV lead: 6947
Sprint Quatro Secure; LV lead: 4194 Attain; right atrial lead:
5554 CapSure). The RA pacing threshold was 0.2 V at 0.5 ms, RV
pacing threshold was 0.6 V at 0.5 ms, and LV pacing threshold was
1.9 V at 0.5 ms without phrenic nerve stimulation. Deﬁbrillation
threshold (DFT) testing was not performed because the patient
had not fully recovered after PCI. The patient’s condition
improved gradually after CRT-D implantation and follow up
CAG was performed on June 7, 2008. No signiﬁcant stenosis was
seen, including in the region of previous PCI. Echocardiography
1 week after CRT-D implantation showed a slightly increased EF
of 41%. On June 11, 2008, DFT testing was planned to conﬁrm the
CRT-D system. Interrogation data did not show remarkable
change compared to the data at implantation. Ventricular ﬁbrilla-
tion (VF) was induced by T wave shock; however, deﬁbrillation
was not achieved due to VF undersensing (under the setting of RV
sensing, 1.2 mV), and sinus rhythm was manually restored after
30–60 s with a shock of 20 J (Fig. 2). We repeated DFT testing afterlsevier B.V. All rights reserved.
Fig. 1. A 12-lead electrocardiogram after cardioversion showing complete atrioventricular block.
Fig. 2. An intracardiac electrocardiogram recorded during DFT testing. Biventricular pacing was performed (mBV) because of VF undersensing, and manual shock was
delivered (* ).
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wave sensing was obtained, and VF was successfully converted
with a shock of 20 J. After DFT testing, the patient complained of
headache and nausea, and his blood pressure dropped to 60 mm
Hg. Chest X-ray showed signiﬁcant congestion of the lungs
and cardiomegaly. Echocardiography showed severely impaired
LV wall motion compared to the results before DFT testing
(Fig. 3). One day after DFT testing, laboratory data conﬁrmed multiple
organ failure (Table 1). Brain, chest, and abdominal CTs wereobtained, but there was no evidence of cerebral infarction, hemor-
rhage, or aortic dissection. The hemodynamic status and clinical
condition of the patient did not improve, and he died after 2 days.2. Discussion
DFT testing is usually recommended to ensure proper func-
tioning of the ICD/CRT-D and verify that there is no acute lead
Table 1
Laboratory data before and after DFT testing.
Test (reference range) 2008/6/9 (Before
DFT testing)
2008/6/12 (1 day
after DFT testing)
WBC (4.08.0109/L) 13.8 15.4
HBG (14.0–17.0 g/dL) 11.4 10.8
PLT (150–350109/L) 363 355
BUN (8.0–19.0 mg/dL) 31.4 51.7
Creatinine (0.80–1.30 mg/L) 1.13 1.40
T-Bil (0.30–1.20 mg/dL) 1.32 1.21
AST (8–38 U/L) 81 1252
ALT (4–44 U/L) 57 1138
LDH (106–220 U/L) 647 2739
CK (54–253 U/L) 637 662
CK-MB (o25%) 43 34
CRP (o0.20 mg/dL) 1.65 4.68
FDP (o10 mg/mL) 17.0 32.8
D-dimer (o1.0 mg/mL) 4.1 14.2
WBC: white blood cell count; HBG: hemoglobin; PLT: platelet; BUN: blood urea
nitrogen; T-Bil: total bilirubin; AST: aspartate aminotransferase; ALT: alamine
aminotransferase; LDH: lactate dehydrogenase; CK: creatinine kinase; CK-MB:
creatinine kinase MB isoenzyme; CRT: C-reactive protein; FDP: ﬁbrin degradation
products.
Fig. 3. Chest X-ray after CRT-D implantation. Leads were located in RAA, RV
septum, and posterior coronary vein.
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VF induction and shock delivery can cause an unstable hemody-
namic condition and clinical deterioration [3,4]. Gasparini et al.
proposed delayed DFT testing for patients with impaired left
ventricular function with a CRT-D [5]. The beneﬁts of delayed DFT
testing are listed as follows: patients with heart failure treated
with CRT-D show marked clinical improvement, and the risk of
lead dislodgement is also reduced. The data obtained from the
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) have
shown that DFT testing is not beneﬁcial for prediction of long-
term mortality or shock efﬁcacy [6], and there are several reports
proposing that there is some uncertainty regarding DFT testing in
patients with severe heart failure from the point of view of safety
[7,8]. Bianchi et al. compared clinical outcomes between 2 patient
groups: those who underwent DFT testing and those who did not,
and they also demonstrated that there was no signiﬁcant differ-
ence in the clinical outcome for 2 years after ICD implantation [9].We encountered several difﬁculties in our case. First, the
patient was recovering after myocardial infarction and cardio-
genic shock, and he might have been unable to tolerate DFT
testing. Current ACC/AHA/ESC guidelines recommend a delay of
40 days as the minimum time prior to ICD implantation [10].
These guidelines are based on the results of the DINAMIT trial
[11], which evaluated the effectiveness of early implantation
(6–40 days after AMI) and failed to demonstrate the efﬁcacy of
ICD therapy to reduce total mortality. However, there remains a
possibility of signiﬁcant reduction of arrhythmic death in some
patients in the early period after AMI. Second, shock delivery was
delayed during DFT testing because of VF undersensing, and it
took some time to restore sinus rhythm. Third, we repeated DFT
testing after changing the RV sensing sensitivity; this extended
DFT testing may have led to hemodynamic instability for this
patient, and his clinical condition deteriorated rapidly into fatal
cardiogenic shock. There might have been preferable options for
this patient, such as: (1) not performing the DFT testing; (2)
postponing the DFT testing until the patient recovered completely
after the AMI; (3) maintaining the temporary pacing until the
clinical condition was more stable and then implanting the ICD or
CRT-D. This case served as an important warning on the manage-
ment of CRT-D in patients with severe heart failure.
In conclusion, our case emphasizes the importance of the
decision whether or not to perform DFT testing as a routine
protocol for patients with severe heart failure. Careful considera-
tion must be given to whether DFT testing should be performed.Conﬂict of interest
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